Breast cancer follow-up: could primary care be the right venue? Curr Med Res Opin. 2006 Apr;22(4):625-30.Jiwa M, Thompson J, Coleman R, Reed M. Breast cancer follow-up: Could primary care be the right venue? Curr Med Res Opin . 2006;22(4):625–30....
摘要: Aims: To identify the elements of a follow-up protocol for treated breast cancer patients in primary care with reference to key stakeholders in one region of the UK.关键词:Breast cancer Follow-up Primary care DOI: 10.1185/030079906X96407 被引量: 31 ...
Patients with early stage breast cancer were eligible. The follow-up protocol was built according to international guidelines. By 2012, 289 NHPs were following 2266 patients treated in 11 centres. Median follow-up time was 7.4 years. The mean intervals between two consecutive consultations were ...
Dixon and Montgomery recommend that breast cancer follow-up be evidence based, flexible, and tailored to patients' needs. 1 Unfortunately neither their proposal to provide only annual clinical review for two years nor the 2002 guideline from the National Institute for Health and Clinical Excellence,...
The delegation of low-risk breast cancer patients' follow-up to non-hospital practitionners (NHP), including gynaecologists and general practitioners, has been assessed prospectively within a care network in the Paris region. Patients with early stage breast cancer were eligible. The follow-up proto...
Furthermore, the lack of well designed, randomised controlled trials on which to base a follow-up protocol for patients with breast cancer is apparent. Conclusion The evidence-base on which these guidelines have been developed is lacking. It is apparent that well designed randomised controlled ...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
6LBA:Minimal vs.maximal invasive axillary management after neoadjuvant systemic therapy in node positive breast cancer:5-year follow-up results of the Dutch MINIMAX registry study 淋巴结阳性乳腺癌新辅助全身治疗后最小与最大侵入腋窝管理:荷兰MINIMAX注册研究的5年随访结果 ...
Respondents mentioned that GPs might need to build up their expertise to ensure quality of care for cancer follow-up, proposing that GPs should be trained in, among others, recognizing and treating (long-term) side effects and in relevant test interpretation. A clear protocol, adjusted for prima...
1% chemotherapy only, and 1% combined endocrine treatment and chemotherapy. The median follow-up times for event-free patients were 15.2 years (IBTR), 15.2 years (any breast cancer recurrence), 20.1 years (BCD) for the indicated endpoint. A flow diagram of the SweBCG91-RT trial is shown ...